13.21
Hutchmed China Limited Adr stock is traded at $13.21, with a volume of 31,439.
It is down -1.34% in the last 24 hours and down -12.27% over the past month.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
See More
Previous Close:
$13.41
Open:
$13.3
24h Volume:
31,439
Relative Volume:
0.35
Market Cap:
$11.51B
Revenue:
$420.26M
Net Income/Loss:
$-41.97M
P/E Ratio:
-52.84
EPS:
-0.25
Net Cash Flow:
$-65.34M
1W Performance:
+0.08%
1M Performance:
-12.27%
6M Performance:
-28.21%
1Y Performance:
-30.91%
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HCM
Hutchmed China Limited Adr
|
13.21 | 2.27B | 420.26M | -41.97M | -65.34M | -0.25 |
![]()
HLN
Haleon Plc Adr
|
11.27 | 49.62B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
165.36 | 72.86B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.78 | 4.35M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.57 | 44.57B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.00 | 19.24B | 16.54B | -1.64B | 749.00M | -1.45 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-13-25 | Downgrade | HSBC Securities | Buy → Hold |
Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy |
May-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
Aug-03-21 | Initiated | Jefferies | Buy |
Oct-02-20 | Initiated | Deutsche Bank | Buy |
Mar-13-20 | Initiated | Cantor Fitzgerald | Overweight |
Feb-20-20 | Initiated | Goldman | Buy |
Nov-19-19 | Initiated | CLSA | Buy |
Oct-23-19 | Reiterated | BofA/Merrill | Buy |
Jul-05-19 | Initiated | Macquarie | Outperform |
View All
Hutchmed China Limited Adr Stock (HCM) Latest News
D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
BNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Jane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Barclays PLC Purchases 2,255 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
UPDATEInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - GlobeNewswire Inc.
International companies to host live webcasts at Deutsche - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter
CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products - AASTOCKS.com
RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance
HUTCHMEDOncology portfolio growth expected to continue - Research Tree
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
Richard Li Invited to Attend China Development Forum, Pictured with Li Qiang and Others - AASTOCKS.com
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne
HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance
CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com
ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com
HUTCHMED Announces NMPA Full Approval for - GlobeNewswire
UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Market news - Research the market
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World
HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire
Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast
Why Alibaba Group Holding Limited (BABA) Is One of the Best ADR Stocks to Invest in? - Yahoo Finance
How Trump and Harris plan to address housing affordability - Yahoo Finance
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® - GlobeNewswire
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance
Hutchmed China Limited Adr Stock (HCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):